Lipoprotein(a) testing initiative
Lipoprotein(a) testing initiative has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Nov 2, 2026: “Closing Gaps in Cardiovascular Risk Detection: Implementing Lipoprotein(a) Testing at Bay Area Community Health”.
1 paper studies it1 findingUpdated
1 new paper in 30 daysSee all 1 papers on lipoprotein(a) testing initiative
At a glance
The findings reach people, from one lab or study. 1 lab.
“Statin therapy rates improved from 70.67% to 79.00%, exceeding BACH's 72% benchmark.”
- 1 lab
- Humans1
What is lipoprotein(a) testing initiative linked with?
1Studies link lipoprotein(a) testing initiative with statin therapy use.
Statin therapy use
upin humans1
1 study
Statin therapy use
upin humans1
Lipoprotein(a) testing initiative is associated with statin therapy use in humans During the Bay Area Community Health lipoprotein(a) testing initiative (70.67% to 79.00%; benchmark 72%).
“Statin therapy rates improved from 70.67% to 79.00%, exceeding BACH's 72% benchmark.”
Human trialDuring the Bay Area Community Health lipoprotein(a) testing initiative
AHA Scientific Sessions 2026 abstract